SUVEN
Life Sciences

CS/NSE/UFR/2011-12
August 13, 2011

TO
THE MANAGER
LISTING DEPARTMENT
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
EXCHANGE PLAZA, BANDRA KURLA COMPLEX
BANDRA (E), MUMBAI - 400 051

Dear Sir/Madam,

Stock Code - SUVEN-EQ

Sub: Notification of Un-audited Financial Results for the quarter ended 30/06/2011 - Clause 41

With Reference to the above subject, we are forwarding here with Un-audited Financial Results of our Company for three months ended 30th June, 2011 in the prescribed Proforma, as required under Clause-41 of the listing agreement as amended. The Board of Directors of our company has taken on record the enclosed Un-audited Financial Results for the 1st Quarter in its meeting held on 13th August, 2011 and Limited Review Report of Auditors of the Company.

Please find enclosed Press release of our company. We request you to take these Documents on your Records

Thanking You,

Yours faithfully,
For **SUVEN LIFE SCIENCES LIMITED**

K HANUMANTHA RAO
Company Secretary

Going beyond Commitment

SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

UN-AUDITED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED 30TH JUNE 2011

(₹ in lacs), except share data

Sl. No.	PARTICULARS	Three Months Ended		Year Ended
		30/06/2011	30/06/2010	31/03/2011
		Unaudited	Unaudited	Audited
1	Income from Sales & Services:	4,473.84	3,616.30	15,104.22
	Less : Excise duly	10.55	23.65	60.84
	Net Income from Sales & Services:	4,463.29	3,592.65	15,043.38
2	**Expenditure**			
	a) Decrease (Increase) in stock in trade	(10.62)	(34.79)	(53.43)
	b) Consumption of raw materials	1,854.11	1,325.04	5,549.85
	c) Purchase of traded goods	-	-	-
	d) Personnel cost	471.47	361.62	1,782.08
	e) Depreciation	138.73	134.24	544.55
	f) Other expenditure - Manufacturing Exps	554.07	479.47	2,082.72
	- Selling Exps	48.41	45.48	261.95
	- Administrative Exps	280.93	230.25	1,029.44
	- R & D Exps	747.82	768.27	3,114.35
	- Provision for Derivatives MTM loses	-	-	-
	g) Total	4,084.92	3,309.58	14,311.51
3	**Profit from operations before Other Income, Interest & Exceptional Items (1-2)**	378.37	283.07	731.87
4	Other Income	20.28	38.24	125.74
5	**Profit before Interest & Exceptional Items (3+4)**	398.65	321.31	857.61
6	Interest	163.58	108.33	532.17
7	**Profit after Interest but before Exceptional Items (5-6)**	235.07	212.98	325.44
8	Exceptional Items	-	-	-
9	**Profit/Loss from Ordinary Activities before tax (7-8)**	235.07	212.98	325.44
10	Tax Expenses	(101.02)	(131.60)	(714.50)
11	**Net Profit(+)/Loss(-) from Ordinary Activities after tax (9-10)**	336.09	344.58	1,039.94
12	Extraordinary Items	-	-	-
13	**Net Profit (+)/Loss(-) for the period (11-12)**	336.09	344.58	1,039.94
14	Paid-up equity share capital	1,167.32	1,165.36	1,167.32
	(Face Value of the Share)	Re.1.00	Re.1.00	Re.1.00
15	Reserves excluding revaluation Reserves as per balance sheet of previous accounting year	-	-	11,506.42
16	**Earning Per Share (EPS)**			
	a) Basic and diluted EPS before extra ordinary items	0.29	0.30	0.89
	b) Basic and diluted EPS after extra ordinary items to date and for the previous year (not annualised)	0.29	0.30	0.89
17	Public share holdings			
	- Number of shares	42,858,960	43,881,220	42,858,960
	- Percentage of Share holding	36.72%	37.65%	36.72%
18	**Promoters and promoter group Shareholding**			
	a) Pledged / Encumbered - Number of shares	-	-	-
	- Percentage of Shares (on promoter & promoter group)	-	-	-
	- Percentage of Shares (on total share capital of the company)	-	-	-
	b) Non-Encumbered - Number of shares	73,873,028	72,655,028	73,873,028
	- Percentage of Shares (on promoter & promoter group)	100.00%	100.00%	100.00%
	- Percentage of Shares (on total share capital of the company)	63.28%	62.35%	63.28%

For SUVEN LIFE SCIENCES LTD

VENKAT JASTI
Chairman & CEO

Place : Hyderabad
Date : 13/08/2011

SUVEN LIFE SCIENCES LTD. HYDERABAD

We Deliver

Going beyond Commitment

SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED FOR THE THREE MONTHS ENDED 30TH JUNE 2011

(₹ in lacs)

Sl. No.	PARTICULARS	Three Months Ended		Year Ended
		30/06/2011	30/06/2010	31/03/2011
		Unaudited	Unaudited	Audited
1	**SEGMENT REVENUE :-**			
	a) Manufaturing (CRAMS)	**4,315.62**	**3,082.84**	**12,675.22**
	b) Services (DDDSS)	**158.22**	**533.46**	**2,429.01**
	c) Research & Development	-	-	-
	Net Sales from Operations	**4,473.84**	**3,616.30**	**15,104.23**
2	**SEGMENT RESULTS :-**			
	Profit/(Loss) before tax and interest:			
	a) Manufaturing (CRAMS)	**1,327.31**	943.32	**3,494.25**
	b) Services (DDDSS)	**68.55**	226.99	**1,063.51**
	c) Research & Development	**(747.82)**	(768.27)	**(3,114.35)**
	TOTAL	**648.04**	402.04	**1,443.41**
Less:	i) Interest	**163.58**	108.33	**532.17**
	ii) Other Un-allocable exps net off un-allocable Income	**249.39**	80.73	**585.80**
	Total Profit Before Tax	**235.07**	**212.98**	**325.44**
3	**CAPITAL EMPLOYED**			
	(Segment Assets - Segment Liabilities)			
	a) Manufaturing (CRAMS)	**11,276.13**	11,185.61	**12,075.70**
	b) Services (DDDSS)	**712.73**	957.06	**629.97**
	c) Research & Development	**3,513.00**	3,170.25	**3,506.95**
	d) Net assets which are not segmented and used commonly	**3,494.93**	1,640.48	**3,036.80**
	TOTAL	**18,996.79**	16,953.40	**19,249.42**

Notes: 1)The above un-audited results were approved and taken on record at the Board of Directors' meeting held on 13th August 2011

2) Status of investor grievence :- Opening bal : Nil, Received : 22, Resolved : 22, Closing bal : Nil

3) Previous's years figures have been regrouped / reclassified whenever necessary.

4) The limited review has been completed by the Statutary Auditors.

For SUVEN LIFE SCIENCES LTD

SUVEN LIFE SCIENCES LTD. HYDERABAD

VENKAT JASTI
Chairman & CEO

Place : Hyderabad
Date : 13/08/2011

We Deliver

KARVY & CO
CHARTERED ACCOUNTANTS

Ref No.LR/001/2011-12:

LIMITED AUDIT REVIEW REPORT

To

The National Stock Exchange Limited
Mumbai.

We have reviewed the accompanying statement of unaudited financial results of M/S. SUVEN LIFE SCIENCES LIMITED, having registered office at 8-2-334, 6th Floor, SDE Serene Chambers, Road No 7, Banjara Hills, Hyderabad – 34, for the period ended on 30.06.2011, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

for KARVY & CO.,
Chartered Accountants
(Registration No.001757S)

KARVY & CO :: Chartered Accountants Firm No. 001757S :: HYDERABAD.

(K. AJAY KUMAR)
PARTNER
M.No.21989

Place: Hyderabad
Date : 13.08.2011.

SUVEN Life Sciences

News Release

Suven's revenue up by 24% and spends 17% of revenue on R&D

HYDERABAD, INDIA (13 August, 2011) - *SUVEN LIFE SCIENCES LIMITED, a bio-pharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its un-audited financial results for the quarter ended 30th June 2011.* The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on13th Aug 2011 at Hyderabad.

Financial Highlights for the 4rth Quarter ended June' 2011:

Growth in revenue	Rs 448.4 mil vs. Rs 363.1 mil	- 23.48%
Growth in PAT	Rs 33.6 mil vs. Rs 34.4 mil	- (2.46%)
Growth in EBIDTA	Rs 53.7 mil vs. Rs 45.5 mil	- 17.96%

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 74.8 mil (16.68% on revenue) for the quarter ended June' 2011.

During the quarter there were major qualitative achievements with the grant of 13 product patents to Suven's drug discovery pipeline which consists of 13 molecules out of which twelve (12) molecules currently in pre-clinical stage of development targeting conditions such as ADHD, Dementia, Depression, Huntington's disease, Parkinson's disease and obesity in addition to **developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia**

Also during the quarter, Suven's Alzheimer drug candidate SUVN-502 successfully completed all chronic toxicological (tox) studies and demonstrated very high margin of safety (MOS) , bags "Bio-Excellence Award at Bangalore India Bio 2011" and UNIT-III RECEIVES US FDA ACCEPTANCE.

For more information on Suven please visit our Web site at http://www.suven.com

Risk Statement:
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;

6/F, Serene Chambers, Road # 5, Banjara Hills Hyderabad 500034, India
Tel: 9140 2354 1142 Fax: 9140 2354 1152 Email: info@suven.com

SUVEN LIFE SCIENCES LTD. HYDERABAD